Current and emerging therapies for acute myeloid leukemia
Open Access
- 1 January 2009
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 31, 2349-2370
- https://doi.org/10.1016/j.clinthera.2009.11.017
Abstract
No abstract availableThis publication has 147 references indexed in Scilit:
- Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk FeaturesClinical Cancer Research, 2008
- Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cellsBritish Journal of Cancer, 2007
- Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplantBone Marrow Transplantation, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome predictionBlood, 2006
- Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trialBlood, 2006
- Purine Nucleoside Analogues in the Treatment of Myleoid LeukemiasLeukemia & Lymphoma, 2003